close

Fundraisings and IPOs

Date: 2018-05-29

Type of information: Private placement

Company: Mereo BioPharma (UK)

Investors:

Amount:

Funding type: private placement

Planned used:

Others:

  • • On May 29, 2018, Mereo BioPharma Group announced that the company has placed 50,076 ordinary shares of 0.3 pence each via PrimaryBid at 300p per ordinary share. The company will allot and issue 50,076 new ordinary shares  pursuant to the offer. Application will be made for the new ordinary shares to be admitted to trading on AIM, which is anticipated to occur on or around 1 June 2018. The New ordinary shares will rank pari passu with the existing ordinary shares of the company.
  • Following admission, the company will have 71,145,050 ordinary shares in issue with voting rights. The company does not hold any ordinary shares in treasury and accordingly there are no voting rights in respect of any treasury shares. Therefore, the total number of voting rights in the company with effect from admission will be 71,145,050. This figure may be used by shareholders of the company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the company, under the financial conduct authority’s disclosure guidance and transparency rules.
  • • On May 25, 2018, Mereo BioPharma Group announced, an offer via PrimaryBid by the issue and allotment by the company of new ordinary shares of 0.3pence each in the company at an issue price of 300 pence per new ordinary share, being a discount of 7.1 per cent to the closing mid-price on 24 May 2018. The offer will be open to individual and institutional investors from 4.30 p.m. on Friday 25 May 2018 to 5.00 p.m. on Monday 28 May 2018. Subscriptions under the offer will be considered by the company in conjunction with PrimaryBid on a "first come, first served" basis, subject to conditions (which are available to view on PrimaryBid.com) with any investment request over £50,000 first requiring consultation with the Company.
  • PrimaryBid is acting as arranger to the Offer. No commission is charged to investors on applications to participate in the Offer made through PrimaryBid. It is vital to note that once an application for New Ordinary Shares has been made and accepted via PrimaryBid, an application cannot be withdrawn.

Therapeutic area: Rare diseases

Is general: Yes